Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Cancer Peptide Vaccine Earns Second Orphan Drug Designation of 2017

OCTOBER 10, 2017
Mathew Shanley
Boston Biomedical has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DSP-7888, a vaccine for the treatment of patients with brain cancer.

Today’s announcement marks the second orphan drug designation of 2017 for the investigational cancer peptide vaccine. The first came in June when the therapy was recognized for the treatment of myelodysplastic syndrome (MDS).

While brain tumors aren’t known to spread to other parts of the body, many spread throughout the brain tissue, and even benign tumors can cause permanent and sometimes fatal damage. The American Cancer Society estimates that more than 23,000 malignant brain or spinal cord tumors will be diagnosed in the US in 2017, resulting in almost 17,000 deaths.

The peptides that make up DSP-7888 vaccine are intended to induce Wilms’ tumor gene 1 (WT1)-specific cytotoxic T lymphocytes and helper T cells, which attack WT1-expressing cancerous cells found in many types of hematologic and solid cancers. The National Cancer Institute has previously ranked WT1 as the top priority target for cancer immunotherapy.

"We are pleased to receive the second orphan drug designation for DSP-7888 this year, which strengthens our belief in this innovative cancer therapy and its potential to provide a meaningful treatment advancement for people with brain cancer who often face a poor prognosis," said Patricia S. Andrews, Chief Executive Officer, Boston Biomedical, Inc. in a press release.

The potential therapy is currently being evaluated in several phase 1 and phase 2 studies, including:
  • A phase 1/2 study in myelodysplastic syndrome (NCT2436252)
  • A phase 1/2 study in pediatric patients with relapsed or refractory high grade gliomas (NCT02750891)
  • A phase 1 study in advanced malignancies (NCT02498665)
Additionally, the drug is being evaluated in combination with bevacizumab in a phase 2 study in patients with recurrent or progressive glioblastoma (NCT03149003). It is anticipated that by adding helper T-cell peptides to the killer peptide treatment alone, improved efficacy may be achieved.
"We are dedicated to developing novel treatments for patients with high unmet need malignancies and look forward to further study of this candidate," said Andrews.

For more from the FDA, including applications, designations and approvals, follow RDR on Facebook and Twitter.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.